biotech.today

Details

  • ●Modalities: small molecules
  • ●Therapeutic areas: undisclosed — multi-therapeutic
  • ●Key targets: undisclosed protein targets
  • ●Indications: undisclosed
  • ●Funding: Alphabet-funded (undisclosed)

Partners & investors

  • Alphabet / Google· Investor

Key considerations

  • ●AI tools in use: AlphaFold 3, AlphaFold 2, Google DeepMind proprietary models
  • ●AlphaFold 3 co-development with DeepMind
  • ●Nobel Prize 2024 (Jumper & Hassabis for AlphaFold)
  • ●$3B+ in pharma deal value (Novartis + Eli Lilly, Jan 2024)

Pipeline

    Get live updates on Isomorphic Labs’s hiring, filings, and partnerships. Follow in BT Pro →
    Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)

    Key people

    Demis Hassabis

    Founder & CEO

    artificial intelligencecomputational biologyNobel laureate

    Max Jaderberg

    COO

    deep learningcomputer visionAI drug discovery
    Visit website →LinkedIn →